Sullivan & Cromwell Reps Amgen In $1B BioVex Deal
Amgen Inc. has agreed to pay up to $1 billion to acquire Woburn, Mass.-based biotechnology company BioVex Group Inc., the maker of an experimental cancer vaccine....To view the full article, register now.
Already a subscriber? Click here to view full article